In this retrospective cohort study, adults (1889 years) undergoing outpatient esophagogastroduodenoscopy or colonoscopy within the HCA Healthcare network from 1 July 2021 to 31 March 2024 were identified
Tirzepatide: A GIP/GLP-1 Dual Agonist for MASH. The New England Journal of Medicine , 2024, www.nejm.org/doi/full/10.1056/NEJMoa2401943
GSH reduces the oxidized catalytic cysteine (Cys47-SOH) of PRDX6, sustaining its peroxidase activity against lipid peroxides, like GPX4, and linking PRDX6 directly to ferroptosis resistance (Fig
Intermittent fasting, Paleolithic, or Mediterranean diets in the real world: exploratory secondary analyses of a weight-loss trial that included choice of diet and exercise
"BPC 157 and standard angiogenic growth factors: Gastrointestinal tract healing, lessons learned from tendon, ligament, muscle and bone healing." Current Pharmaceutical Design